CIK 0001816736 · Large accelerated filer
Disc Medicine, Inc.
Sign in to watch- Ticker
- IRON
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 851612845
- Phone
- (617) 674-9274
- Business address
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Former names
- Gemini Therapeutics, Inc. /DE, FS Development Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $14,489,047
- in 7 filings, $12.6M under 10b5-1 plans
Net −$14,489,047. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-08 | Bitterman Kevin Director | Sale | −13,267 | $72.39 | $960K | 500,621 |
| 2025-10-07 | Bitterman Kevin Director | Sale | −11,378 | $68.01 | $774K | 579,243 |
| 2025-10-07 | Bitterman Kevin Director | Sale | −6,661 | $69.01 | $460K | 572,582 |
| 2025-09-16 | GEMAYEL GEORGES Director | Grant or award · Stock Option (Right to Buy) | +1,000 | 1,000 | ||
| 2025-09-09 | Quisel John D Chief Executive Officer | Option exercise | +10,000 | $1.01 | $10K | 171,828 |
| 2025-09-09 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −10,000 | 198,420 | ||
| 2025-08-22 | Bitterman Kevin Director | Sale 10b5-1 | −2,287 | $61.03 | $140K | 590,621 |
| 2025-08-14 | Bitterman Kevin Director | Sale 10b5-1 | −7,212 | $60.99 | $440K | 592,908 |
| 2025-08-13 | Bitterman Kevin Director | Sale 10b5-1 | −24,962 | $61.15 | $1.5M | 600,120 |
| 2025-08-05 | Bitterman Kevin Director | Sale 10b5-1 | −395 | $60.95 | $24K | 625,082 |
| 2025-07-30 | Bitterman Kevin Director | Sale 10b5-1 | −8,492 | $61.04 | $518K | 625,477 |
| 2025-07-24 | Bitterman Kevin Director | Sale | −13,033 | $61.17 | $797K | 633,969 |
| 2025-07-23 | Bitterman Kevin Director | Sale | −29,837 | $60.97 | $1.8M | 647,002 |
| 2025-07-18 | Bitterman Kevin Director | Sale | −664 | $61.13 | $41K | 676,839 |
| 2025-07-17 | Franchi Jean M. Chief Financial Officer | Sale 10b5-1 | −2,031 | $59.00 | $120K | 63,499 |
| 2025-07-14 | AHMED NADIM Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2025-07-10 | Franchi Jean M. Chief Financial Officer | Sale 10b5-1 | −2,000 | $57.50 | $115K | 65,530 |
| 2025-07-09 | Quisel John D Chief Executive Officer | Option exercise 10b5-1 | +34,800 | $9.86 | $343K | 196,628 |
| 2025-07-09 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −31,207 | $55.23 | $1.7M | 165,421 |
| 2025-07-09 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −3,593 | $56.20 | $202K | 161,828 |
Page 11 of 17 · 337 trades